Clinical Trial Search

Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants

Primary: Mortality — 18; 13 Participants

Primary: Coagulopathy Associated With COVID-19 — -313; -129.5 ng/mL FEU

Primary: PaO2/FiO2 Change (Increase) From Pre-to-post Intervention — 16.9; 29.8 percent change

Primary: Total Number of Patients Who Were Alive and Without Venous/Thrombotic Events in ICU — 28; 31 Participants

Primary: Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial…

Primary: Plasma Viscosity — 2.35; 2.47; 1.61; 2.47 cP

Primary: Safety of In-hospital Thromboprophylaxis as Assessed by Number of Participants With ISTH-defined Clinically-relevant Bleeding Events During Hospitalization — 0…

Primary: Venous or Arterial Thrombotic Events: Full-dose Anticoagulation Versus Standard-dose Prophylactic Anticoagulation — 4,486; 2,351 Number of wins — p=0.028

Primary: Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Day 30 ± 2 Days. — 25; 31 Participants

Primary: Percent Change in D-dimer — -5.6; -2.4 percent daily change — p=0.24

Primary: Change in Activated Partial Thromboplastin Time (APTT) > 1.5 Seconds — 0.95; 1.10 ratio

Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05

Primary: Efficacy - PaO2/FiO2 Ratio — 227; 209; 155; 248 mmHg (rounded)

Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants

Primary: Number of Participants With Inflammatory Marker Reduction of at Least 50% at Any Efficacy Time Point — 5; 8 Participants — p=0.16

Primary: Median Liver Stiffness Value — 7.70; 6.90 kPa — p=0.043

Primary: Survival — 9; 5 Participants

Primary: Acute Physiology and Chronic Health Evaluation II Score — 13.1; 18.3 score on a scale

Primary: Hospital Length of Stay (LOS) — 5; 10; 25 days

Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants

Primary: Estimate the Proportion of Patients With Normal Perfusion Versus Area(s) of Hypoperfusion in Heart, Kidneys and/or Brain — 2; 1 Participants

Primary: 21 Day Organ Support (Respiratory or Vasopressor) Free Days — 22; 22; 17; 17 days — p=.6778

Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants

Primary: Cumulative Number of Hospitalizations or Deaths Prior to Hospitalization — 17; 37 Participants — p=0.005

Primary: 28 Day In-hospital Mortality — 20; 11 participants — p=0.04

Primary: Number of Participants With Major Bleeding Events — 1; 4 Participants

Primary: Success of Administering Plasma — 10; 0 Participants

Primary: Subjects Discharged From the Hospital Alive and Without the Need for Mechanical Ventilation. — 10; 10 Participants

Primary: Mechanical Ventilation or Death Endpoint — 2; 0 Participants